Preclinical Characterization of BCX7353, an Oral Plasma Kallikrein Inhibitor, for the Treatment of Hereditary Angioedema (HAE)

被引：2
|
作者：
Chen, Xilin [1 ]
Kotian, Pravin [1 ]
Wilson, Ramanda [1 ]
Parker, Cynthia D. [1 ]
Babu, Y. S. [1 ]
机构：
[1] Biocryst Pharmaceut Inc, Birmingham, AL USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2017年 / 139卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2016.12.741
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
722
引用
收藏
页码：AB230 / AB230
页数：1
相关论文
共 50 条
  • [1] Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema
    Hwang, Jacqueline R.
    Hwang, Gloria
    Johri, Ansh
    Craig, Timothy
    [J]. IMMUNOTHERAPY, 2019, 11 (17) : 1439 - 1444
  • [2] Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)
    Kotian, Pravin L.
    Wu, Minwan
    Vadlakonda, Satish
    Chintareddy, Venkat
    Lu, Pengcheng
    Juarez, Luis
    Kellogg-Yelder, Debra
    Chen, Xilin
    Muppa, Saritha
    Chambers-Wilson, Ramanda
    Parker, Cynthia Davis
    Williams, Jason
    Polach, Kevin J.
    Zhang, Weihe
    Raman, Krishnan
    Babu, Yarlagadda S.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (17) : 12453 - 12468
  • [3] Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial
    Longhurst, Hilary
    Moldovan, Dumitru
    Bygum, Anette
    Cicardi, Marco
    Huissoon, Aarnoud
    Aygoren-Pursun, Emel
    Grivcheva-Panovska, Vesna
    Hagin, David
    Steiner, Urs
    Stobiecki, Marcin
    Aberer, Werner
    Bethune, Claire
    Faust, Saul N.
    Kiani, Sorena
    Launay, David
    Maurer, Marcus
    Rae, William
    Reshef, Avner
    Cornpropst, Melanie T.
    Dobo, Sylvia M.
    VanDyke, Sharon
    Murray, Sharon
    Collis, Phillip J.
    Sheridan, William P.
    Farkas, Henriette
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB37 - AB37
  • [4] Final results from the ZENITH-1 study: Oral administration of plasma kallikrein inhibitor BCX7353 for the treatment of attacks in patients with hereditary angioedema
    Longhurst, H. J.
    Stobiecki, M.
    Zanichelli, A.
    Huissoon, A.
    Moldovan, D.
    Maurer, M.
    Magerl, M.
    Cancian, M.
    Senter, R.
    Manson, A.
    Aygoeren-Puersuen, E.
    Grivcheva-Panovska, V
    Hagin, D.
    Steiner, U.
    Kiani-Alikhan, S.
    Agmon-Levin, N.
    Bygum, A.
    Aberer, W.
    Faust, S. N.
    Launay, D.
    Gompels, M.
    Triggiani, M.
    Bethune, C.
    Reshef, A.
    Cornpropst, M.
    Dobo, S.
    Van Dyke, S.
    Murray, S.
    Collis, P.
    Sheridan, W. P.
    Farkas, H.
    Cicardi, M.
    [J]. ALLERGY, 2019, 74 : 10 - 11
  • [5] PHARMACOKINETICS AND PHARMACODYNAMICS OF BCX7353, AN ORAL PLASMA KALLIKREIN INHIBITOR, IN HEALTHY JAPANESE SUBJECTS
    Cornpropst, M.
    Dobo, S.
    Collis, P.
    Collier, J.
    Sheridan, W.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S33 - S33
  • [6] SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY
    Riedl, M.
    Lumry, W.
    Banerji, A.
    Aygoren-Pursun, E.
    Bernstein, J.
    Maurer, M.
    Cicardi, M.
    Christiansen, S.
    Zuraw, B.
    Dobo, S.
    Cornpropst, M.
    Iocca, H.
    Nagy, E.
    Murray, S.
    Collis, P.
    Sheridan, W.
    Johnston, D.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S28 - S29
  • [7] Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies
    Manning, Michael E.
    Kashkin, Jay M.
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2021, 42 (04) : 274 - 282
  • [8] Long-term safety and tolerability of Berotralstat (BCX7353) for Hereditary Angioedema (HAE) prophylaxis: APeX-S study results
    Farkas, H.
    Wu, A. Y.
    Kiani, S.
    Reshef, A.
    Stobiecki, M.
    Kinaciyan, T.
    Maurer, M.
    Aygoren-Pursun, E.
    Dix, D.
    Dobo, S.
    Iocca, H.
    Murray, S.
    Sheridan, W. P.
    Peter, J.
    [J]. ALLERGY, 2020, 75 : 58 - 59
  • [9] Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients
    Magerl, M.
    Rae, W.
    Aygoren-Pursun, E.
    Bygum, A.
    Panovska, V. G.
    Steiner, U. C.
    Huissoon, A.
    Longhurst, H.
    Triggiani, M.
    Fain, O.
    Gobert, D.
    Lleonart, R.
    Gonzalez-Quevedo, T.
    Baeza, M. L.
    Du Thanh, A.
    Aberer, W.
    Fang, L.
    Murray, S.
    Clemons, D.
    Sheridan, W.
    Joseph, K.
    Dobo, S.
    Collis, P.
    Cornpropst, M.
    Weller, K.
    Maurer, M.
    [J]. ALLERGY, 2018, 73 : 414 - 414
  • [10] Gastrointestinal (GI) Adverse Events (AEs) Observed With Berotralstat (BCX7353) Treatment for Hereditary Angioedema (HAE) are Primarily Mild, Self-limited, and Diminish with Time on Treatment
    Johnston, Douglas
    Lumry, William
    Banerji, Aleena
    Aygoren-Pursun, Emel
    Bernstein, Jonathan
    Maurer, Marcus
    Cicardi, Marco
    Christiansen, Sandra
    Zuraw, Bruce
    Dobo, Sylvia
    Busse, Paula
    Li, Huamin
    Cornpropst, Melanie
    Iocca, Heather
    Nagy, Eniko
    Murray, Sharon
    Collis, Philip
    Sheridan, William
    Riedl, Marc
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB102 - AB102
12345